全文获取类型
收费全文 | 609篇 |
免费 | 37篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 18篇 |
妇产科学 | 25篇 |
基础医学 | 50篇 |
口腔科学 | 54篇 |
临床医学 | 64篇 |
内科学 | 171篇 |
皮肤病学 | 6篇 |
神经病学 | 32篇 |
特种医学 | 29篇 |
外科学 | 124篇 |
综合类 | 6篇 |
预防医学 | 31篇 |
眼科学 | 6篇 |
药学 | 15篇 |
肿瘤学 | 18篇 |
出版年
2021年 | 16篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 10篇 |
2017年 | 6篇 |
2016年 | 12篇 |
2015年 | 15篇 |
2014年 | 19篇 |
2013年 | 23篇 |
2012年 | 21篇 |
2011年 | 30篇 |
2010年 | 27篇 |
2009年 | 23篇 |
2008年 | 33篇 |
2007年 | 26篇 |
2006年 | 27篇 |
2005年 | 14篇 |
2004年 | 13篇 |
2003年 | 16篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 12篇 |
1999年 | 17篇 |
1998年 | 14篇 |
1997年 | 10篇 |
1996年 | 13篇 |
1995年 | 10篇 |
1994年 | 17篇 |
1993年 | 10篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 8篇 |
1989年 | 13篇 |
1988年 | 15篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 15篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 5篇 |
1981年 | 9篇 |
1980年 | 5篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1971年 | 5篇 |
1969年 | 4篇 |
1968年 | 8篇 |
1967年 | 5篇 |
1965年 | 4篇 |
1963年 | 4篇 |
排序方式: 共有652条查询结果,搜索用时 529 毫秒
61.
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. 总被引:1,自引:0,他引:1
Edoardo Giovanni Giannini Domenico Risso Roberto Testa Franco Trevisani Maria Anna Di Nolfo Paolo Del Poggio Luisa Benvegnù Gian Ludovico Rapaccini Fabio Farinati Marco Zoli Franco Borzio Eugenio Caturelli 《Clinical gastroenterology and hepatology》2006,4(11):1378-1384
BACKGROUND & AIMS: It has been suggested that clinically relevant portal hypertension may affect the therapeutic management and prognosis of cirrhotic patients with hepatocellular carcinoma (HCC). Nevertheless, the importance of the presence of esophageal varices in these patients has not yet been addressed formally. In this study our aim was to evaluate the prevalence and prognostic relevance of the presence of esophageal varices in a large series of patients with HCC. METHODS: The prevalence of esophageal varices was evaluated in 1153 HCC patients who were consecutively referred to 10 Italian centers (the Italian Liver Cancer group). Survival was calculated from the time of HCC diagnosis until death or until the most recent follow-up visit, and was evaluated according to the presence or absence of esophageal varices. The independent prognostic meaning of the presence of esophageal varices was evaluated further in a multivariate regression analysis. RESULTS: Esophageal varices were found in 730 patients (63.3%). Patients with varices showed significantly shorter survival times (P < .0001) as compared with patients without varices. Death as a result of bleeding was more common in patients with varices (P = .0127). In multivariate analysis, the presence of esophageal varices was associated independently with poorer survival (adjusted relative risk, 1.25; 95% confidence interval, 1.06-1.48; P = .0095). CONCLUSIONS: More than half of the patients with HCC have esophageal varices. The presence of esophageal varices is associated with a higher risk of death from bleeding, and is an independent determinant of the patient's prognosis. This variable should be taken into account in the diagnostic and therapeutic work-up of HCC patients. 相似文献
62.
Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link 总被引:5,自引:4,他引:5
Griscelli-Bennaceur A; Gluckman E; Scrobohaci ML; Jonveaux P; Vu T; Bazarbachi A; Carosella ED; Sigaux F; Socie G 《Blood》1995,85(5):1354-1363
The association of paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia (AA) raises the yet unresolved questions as to whether these two disorders are different forms of the same disease. We compared two groups of patients with respect to cytogenetic features, glycosylphosphatidylinositol (GPI)-linked protein expression, protein C/protein S/thrombomodulin/antithrombin III activity, and PIG-A gene expression. The first group consisted of eight patients with PNH (defined as positive Ham and sucrose tests at diagnosis), and the second, 37 patients with AA. Twelve patients with AA later developed a PNH clone. Monoclonal antibodies used to study GPI-linked protein expression (CD14 [on monocytes], CD16 [on neutrophils], CD48 [on lymphocytes and monocytes], CD67 [on neutrophils and eosinophils], and, more recently, CD55, CD58, and CD59 [on erythrocytes]) were also tested on a cohort of 20 normal subjects and five patients with constitutional AA. Ham and sucrose tests were performed on the same day as flow- cytometric analysis. Six of 12 patients with AA, who secondarily developed a PNH clone, had clinical symptoms, while all eight patients with PNH had pancytopenia and/or thrombosis and/or hemolytic anemia. Cytogenetic features were normal in all but two patients. Proteins C and S, thrombomodulin, and antithrombin III levels were within the normal range in patients with PNH and in those with AA (with or without a PNH clone). In patients with PNH, CD16 and CD67 expression were deficient in 78% to 98% of the cells and CD14 in 76% to 100%. By comparison, a GPI-linked defect was detected in 13 patients with AA, affecting a mean of 32% and 33% of CD16/CD67 and CD14 cell populations, respectively. Two of three tested patients with PNH and 1 of 12 patients with AA had a defect in the CD48 lymphocyte population. In a follow-up study of our patient cohort, we used the GPI-linked molecules on granulocytes and monocytes investigated earlier and added the study of CD55, CD58, and CD59 on erythrocytes. Two patients with PNH and 14 with AA were studied for 6 to 13 months after the initial study. Among patients with AA, four in whom no GPI-anchoring defect was detected in the first study had no defect in follow-up studies of all blood-cell subsets (including erythrocytes). Analysis of granulocytes, monocytes, and erythrocytes was performed in 7 of 13 AA patients in whom affected monocytes and granulocytes were previously detected. A GPI-anchoring defect was detected on erythrocytes in five of six.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
63.
Jeanne Palmer Xiaoyu Chai Paul J Martin Daniel Weisdorf Yoshihiro Inamoto Joseph Pidala Madan Jagasia Steven Pavletic Corey Cutler Georgia Vogelsang Sally Arai Mary ED Flowers Stephanie J Lee 《Haematologica》2015,100(5):690-695
Failure-free survival, defined as the absence of relapse, non-relapse mortality or addition of another systemic therapy, has been proposed as a potential endpoint for clinical trials, but its use has only been reported for single-center studies. We measured failure-free survival in a prospective observational cohort of patients (n=575) with both newly diagnosed and existing chronic graft-versus-host disease from nine centers. Failure was observed in 389 (68%) patients during the observation period. The median follow up of all patients was 30.9 months, and the median failure-free survival was 9.8 months (63% at 6 months, 45% at 1 year, and 29% at 2 years). Of the variables measured at enrollment, ten were associated with shorter failure-free survival: higher National Institutes of Health 0–3 skin score, higher National Institutes of Health 0–3 gastrointestinal score, worse range of motion summary score, lower forced vital capacity (%), bronchiolitis obliterans syndrome, worse quality of life, moderate to severe hepatic dysfunction, absence of treatment for gastric acid, female donor for male recipient, and prior grade II–IV acute graft-versus-host disease. Addition of a new systemic treatment, the major cause of failure, was associated with an increased risk of subsequent non-relapse mortality (hazard ratio=2.06, 95% confidence interval: 1.29–3.32; P<0.003) and decreased survival (hazard ratio=1.51, 95% confidence interval: 1.04–2.18; P<0.03). These results show that fewer than half of patients on systemic treatment will be failure-free survivors at 1 year, and fewer than a third will reach 2 years without experiencing failure. Better treatments are needed for chronic graft-versus-host disease. Clinicaltrials.gov identifier: . NCT00637689相似文献
64.
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20‐year survey by the Italian Liver Cancer group 下载免费PDF全文
Fabio Farinati Veronica Vanin Anna Giacomin Caterina Pozzan Umberto Cillo Alessandro Vitale Anna Maria Di Nolfo Paolo Del Poggio Luisa Benvegnu' Gianludovico Rapaccini Marco Zoli Franco Borzio Edoardo G. Giannini Eugenio Caturelli Franco Trevisani the Italian Liver Cancer group 《Liver international》2015,35(1):223-231
65.
Statement of problem
The presence of temporomandibular disorders (TMDs) and/or bruxism signs and symptoms may present multifaceted concerns for the prosthodontist.Purpose
The purpose of this systematic review was to evaluate the relationship between prosthetic rehabilitation and TMDs and bruxism.Material and methods
Three research questions were identified based on different clinical scenarios. Should prosthodontics be used to treat TMD and/or bruxism? Can prosthodontics cause TMDs and/or bruxism? How can prosthodontics be performed (for prosthetic reasons) in patients with TMDs and/or bruxism? A systematic search in the PubMed database was performed to identify all randomized clinical trials (RCTs) comparing the effectiveness of prosthodontics with that of other treatments in the management of TMDs and/or bruxism (question 1); clinical trials reporting the onset of TMDs and/or bruxism after the execution of prosthetic treatments in healthy individuals (question 2); and RCTs comparing the effectiveness of different prosthodontics strategies in the management of the prosthetic needs in patients with TMDs and/or bruxism (question 3).Results
No clinical trials of the reviewed topics were found, and a comprehensive review relying on the best available evidence was provided. Bruxism is not linearly related to TMDs, and both of these conditions are multifaceted. Based on the diminished causal role of dental occlusion, prosthetic rehabilitation cannot be recommended as a treatment for the 2 conditions. In theory, they may increase the demand for adaptation beyond the stomatognathic system’s tolerability. No evidence-based guidelines were available for the best strategy for managing prosthetic needs in patients with TMDs and/or bruxism.Conclusions
This systematic review of publications revealed an absence of RCTs on the various topics concerning the relationship between TMD and bruxism and prosthodontics. Based on the best available evidence, prosthetic changes in dental occlusion are not yet acceptable as strategies for solving TMD symptoms or helping an individual stop bruxism. Clinicians should take care when performing irreversible occlusal changes in healthy individuals and in patients with TMD and/or bruxism. 相似文献66.
Amy D. Waterman Marie Morgievich David J. Cohen Zeeshan Butt Harini A. Chakkera Carrie Lindower Rebecca E. Hays Janet M. Hiller Krista L. Lentine Arthur J. Matas Emilio D. Poggio Michael A. Rees James R. Rodrigue Dianne LaPointe Rudow 《Clinical journal of the American Society of Nephrology》2015,10(9):1659-1669
Living donor kidney transplantation (LDKT) offers better quality of life and clinical outcomes, including patient survival, compared with remaining on dialysis or receiving a deceased donor kidney transplant. Although LDKT education within transplant centers for both potential recipients and living donors is very important, outreach and education to kidney patients in settings other than transplant centers and to the general public is also critical to increase access to this highly beneficial treatment. In June 2014, the American Society of Transplantation’s Live Donor Community of Practice, with the support of 10 additional sponsors, convened a consensus conference to determine best practices in LDKT, including a workgroup focused on developing a set of recommendations for optimizing outreach and LDKT education outside of transplant centers. Members of this workgroup performed a structured literature review, conducted teleconference meetings, and met in person at the 2-day conference. Their efforts resulted in consensus around the following recommendations. First, preemptive transplantation should be promoted through increased LDKT education by primary care physicians and community nephrologists. Second, dialysis providers should be trained to educate their own patients about LDKT and deceased donor kidney transplantation. Third, partnerships between community organizations, organ procurement organizations, religious organizations, and transplant centers should be fostered to support transplantation. Fourth, use of technology should be improved or expanded to better educate kidney patients and their support networks. Fifth, LDKT education and outreach should be improved for kidney patients in rural areas. Finally, a consensus-driven, evidence-based public message about LDKT should be developed. Discussion of the effect and potential for implementation around each recommendation is featured, particularly regarding reducing racial and socioeconomic disparities in access to LDKT. To accomplish these recommendations, the entire community of professionals and organizations serving kidney patients must work collaboratively toward ensuring accurate, comprehensive, and up-to-date LDKT education for all patients, thereby reducing barriers to LDKT access and increasing LDKT rates. 相似文献
67.
68.
Epstein-Barr virus lymphoproliferation after bone marrow transplantation 总被引:16,自引:7,他引:16
We review 15 cases of secondary B-cell lymphoproliferative disorders that occurred among 2,475 patients who received allogeneic bone marrow transplants (BMTs) at the Fred Hutchinson Cancer Research Center (Seattle) between 1969 and 1987. The histopathologic findings in 14 of the 15 patients spanned a wide spectrum of lymphoproliferative lesions. One patient had features characteristic of angioimmunoblastic lymphadenopathy. Epstein-Barr virus (EBV) genomic sequences were identified by Southern blot analysis in each of the 13 patients evaluated. Ten of the 12 lesions evaluated originated in donor cells. In two patients, who had mixed chimerism after transplantation, the lesions originated in host cells. The combined evidence from immunoglobulin light chain staining and the analysis of immunoglobulin heavy chain gene rearrangement indicated that the lesions in most patients represented polyclonal proliferations that gave rise to clonal subpopulations. The results indicate an overall actuarial incidence of 0.6% for this complication in BMT recipients. Anti-CD3 monoclonal antibody (MoAb) treatment of acute graft-v-host disease (GVHD) and T cell depletion of the donor marrow were statistically significant risk factors, and GVHD appeared to play a contributing role, particularly in the setting of human leukocyte antigen (HLA) disparity. Two patients had no identifiable risk factors. Prophylaxis or treatment with acyclovir had no detectable effect in the patients; all but two died with uncontrolled lymphoproliferation. 相似文献
69.
Monoclonal antibody BA-1 binds to B lymphocytes, to cells from most cases of non-T acute lymphoblastic leukemia (ALL), and weakly to neutrophils. To determine whether BA-1 also reacts with hematopoietic progenitor cells (HPC), we studied the effect of removal of BA-1+ cells from human bone marrow on the proliferation in vitro of the trilineage precursor cell CFU-GEMM, and on the committed progenitor cells of granulopoiesis (CFU-C) and erythropoiesis (BFU-E/CFU-E). Complement- mediated cytotoxicity using BA-1 at concentrations far beyond those required to lyse BA-1+ bone marrow cells and ALL cells did not result in inhibition of colony formation in any of the assays. A rosette separation method, using ox red blood cells coated with BA-1, resulted in enrichment of HPC in the BA-1-depleted interface, whereas very few HPC were found in the BA-1-enriched pellet. Both methods indicate that BA-1 does not bind to HPC, although binding of the antibody to the lymphohematopoietic stem cell cannot be excluded yet. The high cytotoxic capacity of the IgM antibody BA-1, and the lack of reactivity with HPC, make the antibody particularly suitable for use in autologous bone marrow transplantation for patients with ALL. 相似文献
70.
Deeg HJ; Storb R; Thomas ED; Appelbaum F; Buckner CD; Clift RA; Doney K; Johnson L; Sanders JE; Stewart P; Sullivan KM; Witherspoon RP 《Blood》1983,61(5):954-959
Eight patients with Fanconi's anemia were given cyclophosphamide alone (seven patients) or combined with procarbazine and antithymocyte globulin (one patient) followed by marrow grafts from HLA-identical siblings. All patients had engraftment. Seven developed acute and three chronic graft-versus-host disease (GVHD). Three patients died with GVHD and infectious complications (days 19, 56, and 82) and one with an intracerebral hemorrhage (day 540). Four patients are surviving 647- 3435 days after grafting, two are well, and two have chronic GVHD that is improving. These results show that Fanconi's anemia can be treated successfully by allogeneic marrow transplantation. 相似文献